INmuneBIO

About:

INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.

Website: http://www.inmunebio.com/

Twitter/X: INmuneBio

Top Investors: Alector, Silicon Valley Bank, Toucan Capital

Description:

INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.